Uroxatral: Targeted Relief for Benign Prostatic Hyperplasia Symptoms
Uroxatral
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.73 | $52.00 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $104.00 $85.00 (18%) | 🛒 Add to cart |
| 90 | $1.31 | $156.00 $118.00 (24%) | 🛒 Add to cart |
| 120 | $1.20 | $208.00 $144.00 (31%) | 🛒 Add to cart |
| 180 | $1.10 | $312.00 $198.00 (37%) | 🛒 Add to cart |
| 270 | $1.00 | $468.00 $270.00 (42%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $624.00 $324.00 (48%) | 🛒 Add to cart |
Synonyms | |||
Uroxatral (alfuzosin HCl) is a selective alpha-1 adrenergic receptor antagonist specifically formulated for the management of signs and symptoms associated with benign prostatic hyperplasia (BPH). As an extended-release tablet, it works by relaxing smooth muscle in the prostate and bladder neck, improving urine flow and reducing BPH-related complications. Its unique pharmacokinetic profile offers a favorable balance of efficacy and tolerability, making it a first-line option for men seeking symptomatic relief without compromising daily activities. Clinical studies demonstrate consistent improvement in urinary flow rates and symptom scores, positioning it as a reliable therapeutic choice in urological practice.
Features
- Contains alfuzosin hydrochloride 10 mg as the active pharmaceutical ingredient
- Extended-release formulation for consistent 24-hour plasma concentration
- Selective alpha-1 adrenoreceptor blockade with specificity for genitourinary tissues
- Once-daily dosing regimen for improved patient compliance
- FDA-approved for treatment of symptomatic benign prostatic hyperplasia
- Manufactured under cGMP standards with rigorous quality control
Benefits
- Significantly improves urinary flow rate and reduces residual urine volume
- Provides rapid relief from obstructive and irritative BPH symptoms within weeks
- Reduces incidence of acute urinary retention and need for surgical intervention
- Minimally affects blood pressure in normotensive patients due to uroselectivity
- Enhances quality of life by restoring normal urinary function and sleep patterns
- Does not require dose titration in most patients, simplifying treatment initiation
Common use
Uroxatral is primarily indicated for the treatment of signs and symptoms of benign prostatic hyperplasia in adult males. It is prescribed for patients experiencing moderate to severe lower urinary tract symptoms including weak stream, hesitancy, intermittency, nocturia, urgency, and incomplete bladder emptying. The medication is typically used as long-term management rather than acute intervention, with treatment duration extending from several months to years based on symptomatic response and tolerability. It may be used as monotherapy or in combination with 5-alpha reductase inhibitors for patients with significantly enlarged prostates.
Dosage and direction
The recommended dosage is one 10 mg extended-release tablet taken orally once daily immediately after the same meal each day. Tablets must be swallowed whole and not crushed, chewed, or divided to maintain the extended-release properties. Administration with food is essential to ensure adequate absorption and maintain optimal pharmacokinetic parameters. Dose adjustment is not typically required for elderly patients or those with renal impairment, but caution is advised in hepatic impairment. Treatment response should be evaluated within 2-4 weeks of initiation, with continued therapy based on symptomatic improvement and tolerability.
Precautions
Prior to initiation, patients should undergo proper diagnostic evaluation to confirm BPH and exclude prostate cancer. Orthostatic hypotension may occur, particularly during initial treatment or dose escalation; patients should be cautioned about potential dizziness and syncope. Regular monitoring of blood pressure is recommended, especially in patients with pre-existing hypertension or those taking antihypertensive medications. Patients should avoid activities requiring mental alertness until their response to the medication is established. Special caution is warranted in patients with severe renal impairment (creatinine clearance <30 mL/min) or moderate hepatic impairment.
Contraindications
Uroxatral is contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride or any component of the formulation. It must not be used in patients with moderate to severe hepatic impairment (Child-Pugh categories B and C) due to significantly increased drug exposure. Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, or clarithromycin is contraindicated. The medication is not indicated for use in women or pediatric populations and is contraindicated in patients with a history of orthostatic hypotension.
Possible side effects
The most commonly reported adverse reactions include dizziness (6.3%), upper respiratory tract infection (3.2%), headache (3.2%), and fatigue (3.0%). Postural hypotension occurs in approximately 1% of patients. Less frequent side effects include abdominal pain, dyspepsia, constipation, and syncope (0.2%). Priapism, though rare, constitutes a urological emergency requiring immediate medical attention. Intraoperative floppy iris syndrome has been observed during cataract surgery in patients taking alpha-blockers; ophthalmologists should be informed of current medication use prior to procedures.
Drug interaction
Concomitant administration with other alpha-adrenergic blockers may result in additive hypotensive effects and is not recommended. Concurrent use with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) may potentiate blood pressure-lowering effects. Moderate CYP3A4 inhibitors (erythromycin, aprepitant, diltiazem) may increase alfuzosin exposure; close monitoring is advised. Antihypertensive medications, nitrates, and other vasodilators may enhance hypotensive effects. Alfuzosin does not significantly affect the pharmacokinetics of warfarin, digoxin, or atenolol.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day with food. If the missed dose is not remembered until the next day, the patient should skip the missed dose and resume the regular dosing schedule. Double doses should not be taken to make up for a missed dose. Patients should be educated about maintaining consistent dosing patterns and advised to contact their healthcare provider if multiple doses are missed to determine appropriate management.
Overdose
In cases of overdose, expected manifestations would include pronounced alpha-adrenergic blockade effects such as severe hypotension, dizziness, and syncope. Supportive care should be initiated with immediate cardiovascular monitoring. Treatment may include supine positioning with legs elevated, intravenous fluids, and vasopressors if necessary. Vital signs should be monitored continuously until stabilized. Given the extended-release formulation, gastrointestinal decontamination may be considered if presentation is early after ingestion, though the benefit must be weighed against risk.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Tablets should be kept in their original blister packaging to protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly dispose of unused or expired medication through medication take-back programs or according to FDA-recommended disposal guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made exclusively by qualified healthcare professionals based on individual patient assessment. Patients should not initiate, modify, or discontinue medication without consulting their prescribing physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Always refer to the official prescribing information for complete details.
Reviews
Clinical trials demonstrate that 67% of patients experience significant improvement in International Prostate Symptom Score (IPSS) with Uroxatral treatment. In a 12-month study, peak urinary flow rates improved by an average of 2.3 mL/sec compared to placebo. Patient-reported outcomes indicate particularly high satisfaction with reduced nocturia and improved sleep quality. Urologists note its favorable side effect profile compared to non-selective alpha-blockers, with discontinuation rates due to adverse events remaining below 5% in long-term studies. Real-world evidence supports maintained efficacy over 24 months of continuous therapy with stable safety parameters.